Catalyst

Slingshot members are tracking this event:

FDA Grants Fast Track Designation to Arena Pharmaceuticals' (ARNA) APD418 for Development in Decompensated Heart Failure Patients

Source Link:
http://invest.arenapharm.com/news-releases/news-release-details/fda-grants-fast-track-designation-arena-pharmaceuticals-apd418

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
ARNA
100%
SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Clinical Data FDA granted Fast Track designation for APD418, a β3-adrenergic receptor (AdrR) antagonist and cardiac myotrope, in development for the treatment of decompensated heart failure (DHF).
http://invest.arenap...
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Jan 16, 2020
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Apd418, Acute Decompensated Heart Failure
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.